Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

igational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.

                               CONDENSED STATEMENTS OF OPERATIONS
                      (Unaudited - in thousands, except per share amounts)


                               Three months ended       Nine months ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

     REVENUES
         Royalty                1,505       2,161        5,590        6,245
         Technology sale
          and collaboration
          services              1,508       1,523        4,479        5,002

     Total revenues             3,013       3,684       10,069       11,247

     EXPENSES
         Research and
          development           1,857       5,945       17,701       18,822
         General and
          administrative        1,438       1,757        3,970        5,327

           Total expenses       3,295       7,702       21,671       24,149

     Operating los
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Medical Director of its Frisco facility. , “We are pleased to announce that Dr. ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Manzanares ...
(Date:7/3/2015)... ... 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... reveal biblical truth and expose popular lies regarding proper relationships according to the bible. ... immediately goes into the core of the subject by explaining why certain types of ...
(Date:7/3/2015)... , ... July 03, 2015 , ... The Celebrity Dresses ... cocktail dresses similar to those of celebrities will have the opportunity to get 10% ... checkout. This ensures that people do not have to use coupon codes or remember ...
(Date:7/2/2015)... ... ... is pleased to announce the opening of its newest location in Dallas, Texas. The opening ... yogurt chain was listed as #22 on the Inc. 500 list of fastest growing companies ... is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... 2 American Oriental,Bioengineering (NYSE: AOB ) ... a share repurchase program for the repurchase of ... stock., Purchases under this program may be ... privately negotiated transactions, and accelerated stock,repurchase transactions or ...
... Inc. (OTC,Bulletin Board: IAGX) announced today that it ... (http://www.monavie.com ) that provides for,Celadrin(R) to be ... lubricant, is a joint health breakthrough that,provides fast, ... cell membrane fluidity and elasticity.,Celadrin is a unique, ...
... low-birth-weight girls , , MONDAY, June 2 (HealthDay News) -- Children ... the risk of developing autism, new research shows. , The ... of the study, which was published in the June issue ... at the U.S. Centers for Disease Control and Prevention, helps ...
... Conn., June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... of its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with ... (AML) had been presented at the 44th Annual Meeting ... Illinois., The Phase III trial started in March ...
... researchers at,the American Society of Hypertension (ASH), listening ... may significantly reduce high blood,pressure. This news was ... Twenty-Third,Annual Scientific Meeting and Exposition in New Orleans, ... of rhythmically homogeneous,music!, SonicMood is an Ambient ...
... , - Misys Trade Services, Including Front- ... (FTSE: MSY.L), the global application software and services,company, ... double accolade of,winning two SWIFTReady Gold labels for ... been the first trade services solutions provider to ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces US$75 Million Share Repurchase Program 2Health News:Imagenetix Enters into Business Relationship with MonaVie 2Health News:Being Born Small, Early Raises Autism Risk 2Health News:Being Born Small, Early Raises Autism Risk 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES! 2Health News:Misys Wins Prestigious Gold Labels From SWIFT for Entire Trade Services Solutions Portfolio 2
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
(Date:7/2/2015)... de julio de 2015 BGI anunció hoy ... alto rendimiento en Hong Kong ... Pathologists (CAP). La instalación de BGI en Hong ... de próxima generación que recibe la certificación CAP en ... estándar en prácticas de laboratorio clínico. Junto con el ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2
... 10 Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, ... the company on the pain management market.  The company plans to ... a range of products that address both the acute and chronic ... , , , ...
... Inc. (Nasdaq: YDNT ) today announced that its Board of Directors declared a ... to all shareholders of record on May 22, 2010 . , ... The Company also announced that its Board of Directors elected ... 2003 . He has assumed positions of increasing responsibility in the areas of finance, ...
Cached Medicine Technology:Xanodyne Announces Renewed Focus on Pain Management Market 2Xanodyne Announces Renewed Focus on Pain Management Market 3Xanodyne Announces Renewed Focus on Pain Management Market 4Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or...
A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills....
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
Medicine Products: